Abstract:Background: Pandemic influenza represents a major threat to global health. Vaccination is the most economic and effective strategy to control influenza pandemic. Conventional vaccine approach, despite being effective, has a number of major deficiencies including limited range of protection, total dependence on embryonated eggs for production, and time consuming for vaccine production. There is an urgent need to develop novel vaccine strategies to overcome these deficiencies.Methodology/Principal Findings: The major objective of this work was to develop a novel vaccine strategy combining recombinant haemagglutinin (HA) protein and a master cell (MC) activator C48/80 for intranasal immunization. We demonstrated in BALB/c mice that MC activator C48/80 had strong adjuvant activity when co-administered with recombinant HA protein intranasally. Vaccination with C48/80 significantly increased the serum IgG and mucosal surface IgA antibody responses against HA protein. Such increases correlated with stronger and durable neutralizing antibody activities, offering protection to vaccinated animals from disease progression after challenge with lethal dose of A/California/04/2009 live virus. Furthermore, protected animals demonstrated significant reduction in lung virus titers, minimal structural alteration in lung tissues as well as higher and balanced production of Th1 and Th2 cytokines in the stimulated splenocytes when compared to those without C48/80.Conclusions/Significance: The present study demonstrates that the novel vaccine approach of combining recombinant HA and mucosal adjuvant C48/80 is safe and effective in eliciting protective immunity in mice. Future studies on the mechanism of action of C48/80 and potential combination with other vaccine strategies such as prime and boost approach may help to induce even more potent and broad immune responses against viruses from various clades.

Intranasal Immunization With Recombinant Ha And Mast Cell Activator C48/80 Elicits Protective Immunity Against 2009 Pandemic H1n1 Influenza In Mice

Intranasal Immunization of Mice with Inactivated Virus and Mast Cell Activator C48/80 Elicits Protective Immunity Against Influenza H1 but Not H5.

Immunization with a Low Dose of Hemagglutinin-Encoding Plasmid Protects Against 2009 H1N1 Pandemic Influenza Virus in Mice.

Protective Efficacy of an H1n1 Cold-Adapted Live Vaccine Against the 2009 Pandemic H1n1, Seasonal H1n1, and H5n1 Influenza Viruses in Mice

Response of BALB/c Mice to a Monovalent Influenza A （H1N1） 2009 Split Vaccine

Immunogenicity and Protective Efficacy of a Live Attenuated Vaccine Against the 2009 Pandemic A H1N1 in Mice and Ferrets.

Single-Dose Intranasal Immunisation with Novel Chimeric H1N1 Expressing the Receptor-Binding Domain of SARS-CoV-2 Induces Robust Mucosal Immunity, Tissue-Resident Memory T Cells, and Heterologous Protection in Mice

Protection Against Influenza H7n9 Virus Challenge with A Recombinant Np-M1-Hsp60 Protein Vaccine Construct in Balb/C Mice

Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection

Polycationic HA/CpG Nanoparticles Induce Cross-Protective Influenza Immunity in Mice

Intramuscular and Intranasal Immunization with an H7N9 Influenza Virus-Like Particle Vaccine Protects Mice Against Lethal Influenza Virus Challenge.

Intranasal Vaccination Of Recombinant H5n1 Ha1 Proteins Fused With Foldon And Fc Induces Strong Mucosal Immune Responses With Neutralizing Activity: Implication For Developing Novel Mucosal Influenza Vaccines

A recombinant protein containing influenza viral conserved epitopes and superantigen induces broad-spectrum protection

Intranasal hemagglutinin protein boosters induce robust mucosal immunity and cross-protection against influenza A viral challenge

The protective effect of intranasal immunization with influenza virus recombinant adenovirus vaccine on mucosal and systemic immune response

An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza

Immunization with a Live Attenuated H7N9 Influenza Vaccine Protects Mice Against Lethal Challenge.

Respiratory Vaccination with Hemagglutinin Nanoliposomes Protects Mice from Homologous and Heterologous Strains of Influenza Virus

Intranasal Administration of Chitosan Against Influenza A (H7N9) Virus Infection in a Mouse Model

Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus

An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection